Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612078 | 0.84 | TAAR1 (0.68) | TAAR1DAOGAAKDM4ESMN1; SMN2 | |
| SCHEMBL170930 | 0.84 | ACHE (0.44) | TAAR1ALDH1A1HPGDALOX15ALOX12 | |
| SCHEMBL7701701 | 0.83 | TAAR1 (0.52) | TAAR1ALDH1A1DAOGAAKDM4E | |
| SCHEMBL6206211 | 0.79 | TAAR1 (0.45) | TAAR1ALDH1A1DAOGAAKDM4E | |
| SCHEMBL7030193 | 0.78 | TAAR1 (0.43) | TAAR1ALDH1A1DAOGAAKDM4E | |
| SCHEMBL6085227 | 0.76 | TAAR1 (0.71) | TAAR1ALDH1A1DAOGAASMN1; SMN2 | |
| SCHEMBL18243095 | 0.75 | TAAR1 (0.42) | TAAR1ALDH1A1DAOGAAKDM4E | |
| SCHEMBL170879 | 0.74 | TAAR1 (0.45) | TAAR1ALDH1A1HPGDDAOGAA | |
| SCHEMBL249134 | 0.74 | TAAR1 (0.45) | TAAR1ALDH1A1HPGDDAOGAA | |
| SCHEMBL17552668 | 0.74 | TAAR1 (0.45) | TAAR1ALDH1A1DAOGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3628320-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| EP-3313396-B1 | G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| EP-3628320-A1 | ACC INHIBITORS AND USES THEREOF | Gilead Apollo, LLC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472374-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2776038-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TAAR1 4250/4885ALDH1A1 104/4885HPGD 872/4885 |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | TAAR1 4603/4885ALDH1A1 144/4885HPGD 335/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | TAAR1 3983/4885ALDH1A1 89/4885HPGD 396/4885 |
| US-10472374-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | TAAR1 4250/4885ALDH1A1 104/4885HPGD 872/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | TAAR1 4250/4885ALDH1A1 104/4885HPGD 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.